All In Biotech

Drug Trial Radar · NCT00542997

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy

A Multicentre Study of the Efficacy, Tolerability, Safety, and Pharmacokinetics of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency

Last checked: Nov 19, 2026Latest source record: Sep 1, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

51

Actual

Start

Sep 2007

Primary completion

Aug 2009

Study completion Aug 2009

Sponsor

Lead sponsor
CSL BehringIndustry
Sponsor type
Industry
First posted
Oct 12, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 2 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to assess the efficacy, tolerability, safety and pharmacokinetics of IgPro20 in patients with primary humoral immunodeficiency (PID).

Conditions

  • Common Variable Immunodeficiency
  • X-linked Agammaglobulinemia
  • Autosomal Recessive Agammaglobulinemia

Interventions

  • Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)Biological

    IgPro20 is a liquid formulation of normal human IgG at a concentration of 20% administered as a SC infusion at weekly intervals. The initial weekly dose was determined based on subjects' previous treatment. Dose adjustments could be performed during the wash-in/wash-out period at the discretion of the investigator.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total Serum IgG Trough LevelsTime frame: Up to 6 months prior to first IgPro20 treatment (Pre-study treatment) and Week 12 to 17 (IgPro20 treatment)

Locations

19 sites in 9 countries. Site status is shown where the registry gives one.

  • Study site

    Paris, France

  • Study site

    Berlin, Germany

  • Study site

    Düsseldorf, Germany

  • Study site

    Freiburg im Breisgau, Germany

  • Study site

    Hanover, Germany

  • Study site

    Leipzig, Germany

  • Study site

    Mainz, Germany

  • Study site

    Munich, Germany

  • Study site

    Brescia, Italy

  • Study site

    Warsaw, Poland

  • Study site

    Bucharest, Romania

  • Study site

    Cluj-Napoca, Romania

  • Study site

    Timișoara, Romania

  • Study site

    Barcelona, Spain

  • Study site

    Seville, Spain

  • Study site

    Gothenburg, Sweden

  • Study site

    Bern, Switzerland

  • Study site

    Cardiff, United Kingdom

  • Study site

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.